TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF NORTH AMERICA METHOTREXATE INJECTION MARKET 14
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 16
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 CURRENCY AND PRICING 19
2.5 DBMR TRIPOD DATA VALIDATION MODEL 20
2.6 MULTIVARIATE MODELLING 23
2.7 PRODUCT LIFELINE CURVE 23
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 24
2.9 DBMR MARKET POSITION GRID 25
2.10 MARKET APPLICATION OVERAGE GRID 26
2.11 VENDOR SHARE ANALYSIS 27
2.12 SECONDARY SOURCES 28
2.13 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 32
4.1 PESTEL ANALYSIS 33
4.2 PORTERS FIVE FORCES 34
4.3 PRICING DYNAMICS 35
4.4 INDUSTRIAL INSIGHTS: 36
4.5 CONCLUSION: 36
5 NORTH AMERICA METHOTREXATE INJECTION MARKET: REGULATIONS 37
6 MARKET OVERVIEW 38
6.1 DRIVERS 40
6.1.1 INCREASED PREVALENCE OF CANCER 40
6.1.2 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT LUNG AND BREAST CANCER 40
6.1.3 RISE IN NUMBER OF PATIENTS WITH INFLAMMATORY DISEASES 41

6.2 RESTRAINTS 41
6.2.1 RISE IN COST OF METHOTREXATE 41
6.2.2 SIDE EFFECTS AND COMPLICATIONS WITH USE OF METHOTREXATE 41
6.3 OPPORTUNITIES 42
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 42
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 42
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 43
6.4 CHALLENGES 43
6.4.1 STRINGENT RULES AND REGULATIONS 43
6.4.2 PRODUCT RECALLS 44
6.4.3 RISE IN COMPETITION BETWEEN MARKET PLAYERS 44
7 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY PRODUCT 45
7.1 OVERVIEW 46
7.2 WITHOUT PRESERVATIVES 49
7.3 WITH PRESERVATIVES 49
8 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY TYPE 50
8.1 OVERVIEW 51
8.2 INJECTABLE SOLUTION 54
8.3 SELF-INJECTABLE SOLUTION 54
9 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AVAILABILITY 55
9.1 OVERVIEW 56
9.2 25MG/ML 59
9.3 50MG/2ML 59
10 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DOSAGE FORM 60
10.1 OVERVIEW 61
10.2 SOLUTION 64
10.3 POWDER 64
11 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY APPLICATION 65
11.1 OVERVIEW 66
11.2 CANCER 69
11.2.1 BREAST CANCER 69
11.2.2 LUNG CANCER 69
11.2.3 HEAD AND NECK CANCER 70
11.2.4 BLOOD CANCER 70
11.2.5 GESTATIONAL TROPHOBLASTIC TUMORS 70
11.2.6 OSTEOSARCOMA 70
11.2.7 OTHERS 70
11.3 AUTOIMMUNE DISEASES 70
11.3.1 RHEUMATOID ARTHRITIS 71
11.3.2 PSORIASIS 71
11.3.3 LUPUS 71
11.3.4 LOCALIZED SCLERODERMA 71
11.3.5 SARCOIDOSIS 71
11.3.6 VASCULITIS 71
11.3.7 JUVENILE DERMATOMYOSITIS 71
11.3.8 OTHERS 72
11.4 PREGNANCY 72
12 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY AGE GROUP 73
12.1 OVERVIEW 74
12.2 ADULTS 77
12.3 GERIATRIC 77
12.4 PEDIATRICS 77
13 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY ROUTE OF ADMINISTRATION 78
13.1 OVERVIEW 79
13.2 INTRAMUSCULAR 82
13.3 INTRAVENOUS 82
13.4 INTRA-ARTERIAL 82
13.5 INTRATHECAL 83
14 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY END USER 84
14.1 OVERVIEW 85
14.2 HOSPITALS 88
14.3 CLINICS 88
14.4 HOME HEALTHCARE 89
14.5 OTHERS 89
15 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY DISTRIBUTION CHANNEL 90
15.1 OVERVIEW 91
15.2 HOSPITAL PHARMACY 94
15.3 RETAIL PHARMACY 94
15.4 ONLINE PHARMACY 94
15.5 OTHERS 95

16 NORTH AMERICA METHOTREXATE INJECTION MARKET, BY COUNTRY 96
16.1 U.S. 101
16.2 CANADA 105
16.3 MEXICO 109
17 NORTH AMERICA METHOTREXATE INJECTION MARKET: COMPANY LANDSCAPE 113
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 113
18 SWOT ANALYSIS 114
19 COMPANY PROFILE 115
19.1 PFIZER INC. 115
19.1.1 COMPANY SNAPSHOT 115
19.1.2 REVENUE ANALYSIS 116
19.1.3 PRODUCT PORTFOLIO 116
19.1.4 RECENT DEVELOPMENT 116
19.2 ANTARES PHARMA 117
19.2.1 COMPANY SNAPSHOT 117
19.2.2 REVENUE ANALYSIS 117
19.2.3 PRODUCT PORTFOLIO 118
19.2.4 RECENT DEVELOPMENT 118
19.3 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 119
19.3.1 COMPANY SNAPSHOT 119
19.3.2 REVENUE ANALYSIS 119
19.3.3 PRODUCT PORTFOLIO 120
19.3.4 RECENT DEVELOPMENT 120
19.4 MEDEXUS PHARMACEUTICALS, INC. 121
19.4.1 COMPANY SNAPSHOT 121
19.4.2 REVENUE ANALYSIS 121
19.4.3 PRODUCT PORTFOLIO 122
19.4.4 RECENT DEVELOPMENT 122
19.5 VIATRIS INC. 123
19.5.1 COMPANY SNAPSHOT 123
19.5.2 REVENUE ANALYSIS 124
19.5.3 PRODUCT PORTFOLIO 124
19.5.4 RECENT DEVELOPMENT 124
19.6 ACCORD HEALTHCARE 125
19.6.1 COMPANY SNAPSHOT 125
19.6.2 REVENUE ANALYSIS 125
19.6.3 PRODUCT PORTFOLIO 126
19.6.4 RECENT DEVELOPMENT 126
19.7 CUMBERLAND PHARMACEUTICALS INC. 127
19.7.1 COMPANY SNAPSHOT 127
19.7.2 REVENUE ANALYSIS 127
19.7.3 PRODUCT PORTFOLIO 128
19.7.4 RECENT DEVELOPMENTS 128
19.8 HIKMA PHARMACEUTICALS PLC 129
19.8.1 COMPANY SNAPSHOT 129
19.8.2 REVENUE ANALYSIS 129
19.8.3 PRODUCT PORTFOLIO 130
19.8.4 RECENT DEVELOPMENTS 130
19.9 PV PHARMA 131
19.9.1 COMPANY SNAPSHOT 131
19.9.2 PRODUCT PORTFOLIO 131
19.9.3 RECENT DEVELOPMENT 131
19.10 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG) 132
19.10.1 COMPANY SNAPSHOT 132
19.10.2 REVENUE ANALYSIS 132
19.10.3 PRODUCT PORTFOLIO 133
19.10.4 RECENT DEVELOPMENT 133
19.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 134
19.11.1 COMPANY SNAPSHOT 134
19.11.2 REVENUE ANALYSIS 134
19.11.3 PRODUCT PORTFOLIO 135
19.11.4 RECENT DEVELOPMENT 135
20 QUESTIONNAIRE 136
21 RELATED REPORTS 140

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.